ArticleMolecular imaging2016
Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma.
Article in Molecular imaging, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Preliminary Results on the Added Value of Parametric Images Derived fromMolecular imaging and biology · 2026Article
- Interferon-gamma signaling pathway: Modulation of key genes in the progression of glioblastoma.World journal of biological chemistry · 2025Review
- Preparation ofInternational journal of molecular sciences · 2023Article
- Differential Gene Expression and Methylation Analysis of Melanoma in TCGA Database to Further Study the Expression Pattern of KYNU in Melanoma.Journal of personalized medicine · 2022Article
- Depression and tryptophan metabolism in patients with primary brain tumors: Clinical and molecular imaging correlates.Brain imaging and behavior · 2021Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- The impact of initial tumor microenvironment on imaging phenotype.Cancer treatment and research communications · 2021Article
- Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.International journal of molecular sciences · 2020Review
- Multimodal neuroimaging of gliomatosis cerebri: a case series of four patients.Acta radiologica open · 2020Article
- The Role of Aryl Hydrocarbon Receptor (AhR) in Brain Tumors.International journal of molecular sciences · 2020Review
- Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.Signal transduction and targeted therapy · 2020Article
- The therapeutic potential of targeting tryptophan catabolism in cancer.British journal of cancer · 2020Review
- Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer.EJNMMI radiopharmacy and chemistry · 2019Review
- Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond.Nature reviews. Drug discovery · 2019Review
- Hypoxia Inducible Factor 1α Inhibits the Expression of Immunosuppressive Tryptophan-2,3-Dioxygenase in Glioblastoma.Frontiers in immunology · 2019Article
- Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod.Journal of neuro-oncology · 2019Article
- Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors.Journal of neuro-oncology · 2018Article
- Lycorine inhibits glioblastoma multiforme growth through EGFR suppression.Journal of experimental & clinical cancer research : CR · 2018Article
- Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography.Frontiers in neurology · 2018Review
- Evaluation of radiofluorinated carboximidamides as potential IDO-targeted PET tracers for cancer imaging.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Increasing evidence demonstrates the immunosuppressive kynurenine pathway's (KP) role in the pathophysiology of human gliomas. To study the KP in vivo, we used the noninvasive molecular imaging tracer α-[(11)C]-methyl-l-tryptophan (AMT). The AMT-positron emission tomography (PET) has shown high uptake in high-grade gliomas and predicted survival in patients with recurrent glioblastoma (GBM). We generated patient-derived xenograft (PDX) models from dissociated cells, or tumor fragments, from 5 patients with GBM. Mice bearing subcutaneous tumors were imaged with AMT-PET, and tumors were analyzed to detect the KP enzymes indoleamine 2,3-dioxygenase (IDO) 1, IDO2, tryptophan 2,3-dioxygenase, kynureninase, and kynurenine 3-monooxygenase. Overall, PET imaging showed robust tumoral AMT uptake in PDX mice with prolonged tracer accumulation over 60 minutes, consistent with AMT trapping seen in humans. Immunostained tumor tissues demonstrated positive detection of multiple KP enzymes. Furthermore, intracranial implantation of GBM cells was performed with imaging at both 9 and 14 days postimplant, with a marked increase in AMT uptake at 14 days and a corresponding high level of tissue immunostaining for KP enzymes. These results indicate that our PDX mouse models recapitulate human GBM, including aberrant tryptophan metabolism, and offer an in vivo system for development of targeted therapeutics for patients with GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.